Premium
Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works
Author(s) -
Inoue Sae,
Okiyama Naoko,
Okune Mari,
Shiraki Nagisa,
Kessoku Reiko,
Fujimoto Manabu
Publication year - 2017
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.13561
Subject(s) - essential thrombocythemia , livedo reticularis , medicine , myelofibrosis , polycythaemia , polycythemia vera , pathology , thrombosis , calreticulin , myeloproliferative neoplasm , dermatology , bone marrow , gastroenterology , disease , biology , biochemistry , endoplasmic reticulum
Essential thrombocythemia ( ET ) is a rare clonal myeloproliferative disorder with a prevalence rate of approximately 1–3 cases per 100 000 individuals per year. ET is characterized by a persistent increase in the platelet count with hyperplasia of bone marrow megakaryocytes. It is difficult to make a diagnosis of ET , because most thrombocythemia are reactive to certain disease conditions including iron deficiency anemia, infection, collagen diseases and malignant tumors. Mutation in the Janus kinase ( JAK )2 gene is present in approximately 50–70% of ET patients, and somatic mutations in the calreticulin ( CALR ) gene were recently discovered in approximately 20–25% of sporadic patients with ET or primary myelofibrosis. Various cutaneous manifestations of ET often occur by microvascular thrombosis and precede severe arterial and venous thromboembolic events in other organs. Therefore, in order to prevent such severe events, it is important to make an early diagnosis of ET based on a number of cutaneous manifestations. Here, we report two cases of ET diagnosed based on livedo racemosa on feet with gene mutations in JAK 2 and CALR , respectively, and show the pathological and immunohistological findings of the livedo resulting from platelet thrombosis rather than vasculitis. We also review the cutaneous manifestations in current published reports of Japanese ET patients. Our patients were successfully treated with low‐dose aspirin, a vasodepressor and hydroxyurea, following regressed livedo and reduced platelet counts.